Drug-target identification in Drosophila cells: combining high-throughout RNAi and small-molecule screens
29447 DrugDiscoveryToday2007.pdf (517.4Kb)
Access StatusFull text of the requested work is not available in DASH at this time ("dark deposit"). For more information on dark deposits, see our FAQ.
Eggert, Ulrike S.
MetadataShow full item record
CitationPerrimon, Norbert, Adam Friedman, Bernard Mathey-Prevot, and Ulrike S. Eggert. 2007. “Drug-Target Identification in Drosophila Cells: Combining High-throughout RNAi and Small-Molecule Screens.” Drug Discovery Today 12 (1–2): 28–33. https://doi.org/10.1016/j.drudis.2006.10.006.
AbstractRNA interference (RNAi) and small-molecule approaches are synergistic on multiple levels, from technology and high-throughput screen development to target identification and functional studies. Here, we describe the RNAi screening platform that we have established and made available to the community through the Drosophila RNAi Screening Center at Harvard Medical School. We then illustrate how the combination of RNAi and small-molecule HTS can lead to effective identification of targets in drug discovery.
Citable link to this pagehttp://nrs.harvard.edu/urn-3:HUL.InstRepos:41384467
- HMS Scholarly Articles